Neuland Laboratories Limited has informed the Exchange regarding a revised press release dated May 12, 2026, titled "Press Release on the Financial Results of the Company for the quarter and year ended March 31, 2026".
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Neuland Laboratories reported exceptional Q4 FY26 results with total income of Rs. 788.7 crore, up 134.9% YoY from Rs. 335.8 crore. EBITDA surged to Rs. 319.4 crore with margin expanding to 40.5% from 17.3% in Q4 FY25. Profit after tax more than doubled to Rs. 212.5 crore from Rs. 27.7 crore. The filing corrects an error in the earnings call link from an earlier press release dated May 12, 2026. The company cited good business visibility anchored by commercial molecules and ongoing investments in peptide manufacturing and a new R&D centre.
Strong operational performance with massive margin expansion signals operational efficiency gains. The corrected earnings call link is an administrative fix with no impact on the financial outlook presented.